Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press33810.17650/1994-4098-2008-0-1-52-56GYNECOLOGY. TOPICAL SUBJECTГИНЕКОЛОГИЯ. АКТУАЛЬНАЯ ТЕМАOVARIAN DYSGERMINOMAS: TREATMENT EXPERIENCE OF THE N.N.BLOKHIN CRC RAMSДИСГЕРМИНОМЫ ЯИЧНИКОВ: ОПЫТ ЛЕЧЕНИЯ БОЛЬНЫХ В ГУ РОНЦ ИМ. Н.Н. БЛОХИНА РАМНStreltzovaO. N.СтрельцоваО. Н.
Russian Federation
FedyaninM. Yu.ФедянинМ. Ю.
Russian Federation
TryakinA. A.ТрякинА. А.
Russian Federation
BulanovA. A.БулановА. А.
Russian Federation
ZhordaniaV. V.ЖорданиаК. И.
Russian Federation
TyulandinS. A.ТюляндинС. А.
Russian Federation
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences , MoscowГУ РОНЦ им. Н.Н. Блохина РАМН, Москваru150220082008152561509201415092014Received:15092014Accepted:15092014Published:150220082008https://ojrs.abvpress.ru/ojrs/article/view/338

This is a retrospective review of treatment results of 35 patients with dysgerminomas in the Departments of Clinical Pharmacology and Gynecology, N.N.Blokhin Russian Cancer Research Center (NNBRCRC) between 1990 and 2006.Primary surgery was carried out in all patients. Twenty patients (57%) underwent fertility-sparing surgery. Postoperative systemic chemotherapy was administered to 28 (80%) women: аmong them 23 received platinum-based chemotherapy, 5 were treated with non- platinum combinations.At a median follow-up of 75 months the disease-free survival was 71,4% and the overall survival was 97,1%. Our data confirmed that prog- nosis of dysgerminomas is excellent if managed with standard treatment initially, this is possible, as a rule, only in specialized cancer centers.

ДИСГЕРМИНОМЫ ЯИЧНИКОВ: ОПЫТ ЛЕЧЕНИЯ БОЛЬНЫХ В ГУ РОНЦ ИМ. Н.Н. БЛОХИНА РАМН

1. Quirk J.T., Natarajan N. Ovarian cancer incidence in the United States, 1992— 1999. Gynecol Oncol 2005;97:519—523.Quirk J.T., Natarajan N. Ovarian cancer incidence in the United States, 1992— 1999. Gynecol Oncol 2005;97:519—523.2. Тюляндин С.А. Герминогенные опухоли яичников. Практ онкол 2006;7(1).Тюляндин С.А. Герминогенные опухоли яичников. Практ онкол 2006;7(1).3. Козаченко В.П. Клиническая онкогинекология. Руководство для врачей. М., Медицина; 2005. с. 247— 253.Козаченко В.П. Клиническая онкогинекология. Руководство для врачей. М., Медицина; 2005. с. 247— 253.4. Patterson D.M., Rustin G.J. Controversies in the management of germ cell tumors of the ovary. Curr Opin Oncol 2006;18:500—506.Patterson D.M., Rustin G.J. Controversies in the management of germ cell tumors of the ovary. Curr Opin Oncol 2006;18:500—506.5. Norris H.J., Jensen R.D. Relative fre- quency of ovarian neoplasms in children and adolescents. Cancer 1972;30:713— 719.Norris H.J., Jensen R.D. Relative fre- quency of ovarian neoplasms in children and adolescents. Cancer 1972;30:713— 719.6. Brewer M., Gershenson D.M., Herzog C.E. et al. Outcome and repro- ductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17:2670—2675.Brewer M., Gershenson D.M., Herzog C.E. et al. Outcome and repro- ductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17:2670—2675.7. Lawrence M.R., Talerman A. Recent Advances in the Pathology and Classification Of Ovarian Germ Cell Tumors. Int J of Gynecol Pathology 2006;25:305—320.Lawrence M.R., Talerman A. Recent Advances in the Pathology and Classification Of Ovarian Germ Cell Tumors. Int J of Gynecol Pathology 2006;25:305—320.8. Kurman R.J., Norris H.J. Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases. Obstet Gynecol 1976;48:579—589.Kurman R.J., Norris H.J. Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases. Obstet Gynecol 1976;48:579—589.9. Kurman R.J., Norris H.J. Malignant germ cell tumors of the ovary. Hum Pathol 1977;8:551—564.Kurman R.J., Norris H.J. Malignant germ cell tumors of the ovary. Hum Pathol 1977;8:551—564.10. You W., Dainty L.A., Rose G.S. et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005;105:1405—1409.You W., Dainty L.A., Rose G.S. et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005;105:1405—1409.11. Deligeoroglou E., Eleftheriades M., Shiadoes V. et al. Ovarian masses during adolescence: clinical, ultrasonographic and pathologic findings, serum tumor markers and endocrinological profile. Gynecol Endocrinol 2004;19:1—8.Deligeoroglou E., Eleftheriades M., Shiadoes V. et al. Ovarian masses during adolescence: clinical, ultrasonographic and pathologic findings, serum tumor markers and endocrinological profile. Gynecol Endocrinol 2004;19:1—8.12. Bridgewater J.A., Rustin G.J. Management of nonepithelial ovarian tumours. Oncology 1999;57:89—98.Bridgewater J.A., Rustin G.J. Management of nonepithelial ovarian tumours. Oncology 1999;57:89—98.13. Hurteau J.A., Williams S.J. Ovarian germ cell tumours. Ovarian. Cancer, 2 edn. Rubin S.C., Sutton G.P. (eds). Philadelphia, Lippincott Williams & Wilkins; 2001. p. 373—382.Hurteau J.A., Williams S.J. Ovarian germ cell tumours. Ovarian. Cancer, 2 edn. Rubin S.C., Sutton G.P. (eds). Philadelphia, Lippincott Williams & Wilkins; 2001. p. 373—382.14. Dark G.G., Bower M., Newlands E.S. Surveillance policy for stage I ovarian germ cell tumours. J Clin Oncol 1997; 15:620—624.Dark G.G., Bower M., Newlands E.S. Surveillance policy for stage I ovarian germ cell tumours. J Clin Oncol 1997; 15:620—624.15. Einhorn L.H., Donohue J. Cis- diamminedichloroplatinum, vinblastine, and bleomycin combination chemothera- py in disseminated testicular cancer. Ann Intern Med 1977;87:293—298.Einhorn L.H., Donohue J. Cis- diamminedichloroplatinum, vinblastine, and bleomycin combination chemothera- py in disseminated testicular cancer. Ann Intern Med 1977;87:293—298.16. Gershenson D.M., Morris M., Cangir A. et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:715—720.Gershenson D.M., Morris M., Cangir A. et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:715—720.17. Williams S., Blessing J.A., Liao S.Y. et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin. A trial of the Gynecologic Oncology Group. J Clin Oncol 1994;12:701—706.Williams S., Blessing J.A., Liao S.Y. et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin. A trial of the Gynecologic Oncology Group. J Clin Oncol 1994;12:701—706.18. Gershenson D.M., Wharton J.T., Kline R.C. et al. Chemotherapeutic com- plete remission in patients with metastat- ic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity. Cancer 1986;58:2594—2599.Gershenson D.M., Wharton J.T., Kline R.C. et al. Chemotherapeutic com- plete remission in patients with metastat- ic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity. Cancer 1986;58:2594—2599.19. Williams S.D., Blessing J.A., Hatch K.D. et al. Chemotherapy of advanced dysgerminoma: Trials of the Gynecologic Oncology Group. J Clin Oncol 1991;9:1950—1955.Williams S.D., Blessing J.A., Hatch K.D. et al. Chemotherapy of advanced dysgerminoma: Trials of the Gynecologic Oncology Group. J Clin Oncol 1991;9:1950—1955.20. Williams S.D., Kauderer J., Burnett A.F. et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide. A trial of the Gynecologic Oncology Group. Gynecol Oncol 2004;95: 496—499.Williams S.D., Kauderer J., Burnett A.F. et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide. A trial of the Gynecologic Oncology Group. Gynecol Oncol 2004;95: 496—499.21. Gershenson D.M. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr 2005; 34:43—47.Gershenson D.M. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr 2005; 34:43—47.22. Zanetta G., Bonazzi C., Cantu M. et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19:1015—1020.Zanetta G., Bonazzi C., Cantu M. et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19:1015—1020.23. Zanagnolo V., Sartori E., Trussardi E. et al. Preservation of ovarian function, reproductive ability and emotional atti- tudes in patients with malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol 2005; 123:235—243.Zanagnolo V., Sartori E., Trussardi E. et al. Preservation of ovarian function, reproductive ability and emotional atti- tudes in patients with malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol 2005; 123:235—243.24. Serov S.F., Scully R.E., Sobin L.H. Histological typing of ovarian tumours. International histological classification of tumours, No. 9, Geneva, World Health Organization; 1973.Serov S.F., Scully R.E., Sobin L.H. Histological typing of ovarian tumours. International histological classification of tumours, No. 9, Geneva, World Health Organization; 1973.25. Raghavan D. Atlas of Clinical Oncology. Germ Cell Tumors. London; 2003. p. 39.Raghavan D. Atlas of Clinical Oncology. Germ Cell Tumors. London; 2003. p. 39.26. Zanagnolo V., Sartori E., Galleri G. et al. Clinical review of 55 cases of malig- nant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004; 25:315—320.Zanagnolo V., Sartori E., Galleri G. et al. Clinical review of 55 cases of malig- nant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004; 25:315—320.27. Billmire D., Vinocur C., Rescorla F. et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An intergroup study. J Pediatr Surg 2004;39:424—429.Billmire D., Vinocur C., Rescorla F. et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An intergroup study. J Pediatr Surg 2004;39:424—429.28. Gobel U., Schneider D.T., Calaminus G. et al. Germ-cell tumors in childhood and adolescence: GPOH MAKEI and the MAHO study groups. Ann Oncol 2000;11:263—271.Gobel U., Schneider D.T., Calaminus G. et al. Germ-cell tumors in childhood and adolescence: GPOH MAKEI and the MAHO study groups. Ann Oncol 2000;11:263—271.29. Lai C.H., Chang T.C., Hsueh S. et al. Outcome and prognostic factors in ovari- an germ cell malignancies. Gynecol Oncol 2005;96:784—791.Lai C.H., Chang T.C., Hsueh S. et al. Outcome and prognostic factors in ovari- an germ cell malignancies. Gynecol Oncol 2005;96:784—791.30. Murugaesu N., Schmid P., Dancey G. et al. Malignant ovarian germ cell tumors. Identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006;24:4862—4866.Murugaesu N., Schmid P., Dancey G. et al. Malignant ovarian germ cell tumors. Identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006;24:4862—4866.31. Bower M., Fife K., Holden L. et al. Chemotherapy for ovarian germ cell tumours. Eur J Cancer 1996;32A:593—597.Bower M., Fife K., Holden L. et al. Chemotherapy for ovarian germ cell tumours. Eur J Cancer 1996;32A:593—597.32. Newlands E.S., Bower M., Holden L. et al. Management of Stage I and metasta- tic ovarian germ cell tumors (OGCT). Proc ASCO 1996;15:A774 (abstr.).Newlands E.S., Bower M., Holden L. et al. Management of Stage I and metasta- tic ovarian germ cell tumors (OGCT). Proc ASCO 1996;15:A774 (abstr.).33. Slayton R.E., Park R.C., Silverberg S.G. et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 1985;56:243—248.Slayton R.E., Park R.C., Silverberg S.G. et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 1985;56:243—248.34. Williams S.D., Blessing J.A., Moore D.H. et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 1989;111:22—27.Williams S.D., Blessing J.A., Moore D.H. et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 1989;111:22—27.35. Scully R.E., Sobin L.H. Histological Typing of Ovarian Tumours. World Health Organization International Histological Classification of Tumours (ed 2). Berlin, Germany, Springer; 1999.Scully R.E., Sobin L.H. Histological Typing of Ovarian Tumours. World Health Organization International Histological Classification of Tumours (ed 2). Berlin, Germany, Springer; 1999.36. Leiserowitz G.S., Xing G., Cress R. et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006;1001:315—321.Leiserowitz G.S., Xing G., Cress R. et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006;1001:315—321.